Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 13/20 | 0.76 |
| ▸ | PIK3CA | P42336 | 12/20 | 0.76 |
| ▸ | PIK3CD | O00329 | 10/20 | 0.70 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.67 |
| ▸ | MTOR | P42345 | 1/20 | 0.51 |
| ▸ | BRAF | P15056 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | RAF1 | P04049 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17047482 | 0.90 | PIK3CG (0.82) | PIK3CGPIK3CAPIK3CDPIK3CBBRAF | |
| SCHEMBL17047554 | 0.86 | PIK3CG (1.00) | PIK3CGPIK3CAPIK3CDPIK3CBBRAF | |
| SCHEMBL17047521 | 0.86 | PIK3CG (1.00) | PIK3CGPIK3CAPIK3CDPIK3CBBRAF | |
| SCHEMBL18382227 | 0.84 | MAPKAPK2 (0.55) | PIK3CGPIK3CAPIK3CDPIK3CBMTOR | |
| SCHEMBL17047462 | 0.82 | PIK3CG (1.00) | PIK3CGPIK3CAPIK3CDPIK3CBBRAF | |
| SCHEMBL18382198 | 0.81 | PIK3CG (0.81) | PIK3CGPIK3CAPIK3CDPIK3CBBRAF | |
| SCHEMBL17047493 | 0.81 | PIK3CG (1.00) | PIK3CGPIK3CAPIK3CDPIK3CBBRAF | |
| SCHEMBL17047463 | 0.81 | PIK3CG (0.77) | PIK3CGPIK3CAPIK3CDPIK3CBLMNA | |
| SCHEMBL17047502 | 0.81 | PIK3CA (0.47) | PIK3CGPIK3CAPIK3CDPIK3CBMTOR | |
| SCHEMBL17047466 | 0.81 | PIK3CG (1.00) | PIK3CGPIK3CAPIK3CDPIK3CBBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202374-B2 | 6-aryl-4-phenylamino-quinazoline analogs as phosphoinositide-3-kinase inhibitors | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2019-02-12 | — | — | US | disclosed |
| US-10202374-B2 | 6-aryl-4-phenylamino-quinazoline analogs as phosphoinositide-3-kinase inhibitors | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2019-02-12 | — | — | US | disclosed |
| EP-3110801-B1 | 6-ARYL-4-PHENYLAMINO-QUINAZOLINE ANALOGS AS PHOSPHOINOSITIDE-3-KINASE INHIBITORS | COUNCIL SCIENT IND RES (IN) | 2019-01-30 | — | — | EP | disclosed |
| EP-3110801-B1 | 6-ARYL-4-PHENYLAMINO-QUINAZOLINE ANALOGS AS PHOSPHOINOSITIDE-3-KINASE INHIBITORS | COUNCIL SCIENT IND RES (IN) | 2019-01-30 | — | — | EP | disclosed |
| US-20170015662-A1 | 6-ARYL-4-PHENYLAMINO-QUINAZOLINE ANALOGS AS PHOSPHOINOSITIDE-3-KINASE INHIBITORS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2017-01-19 | — | — | US | disclosed |
| US-20170015662-A1 | 6-ARYL-4-PHENYLAMINO-QUINAZOLINE ANALOGS AS PHOSPHOINOSITIDE-3-KINASE INHIBITORS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2017-01-19 | — | — | US | disclosed |
| US-20170015662-A1 | 6-ARYL-4-PHENYLAMINO-QUINAZOLINE ANALOGS AS PHOSPHOINOSITIDE-3-KINASE INHIBITORS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2017-01-19 | — | — | US | disclosed |
| EP-3110801-A1 | 6-ARYL-4-PHENYLAMINO-QUINAZOLINE ANALOGS AS PHOSPHOINOSITIDE-3-KINASE INHIBITORS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2017-01-04 | — | — | EP | disclosed |
| WO-2015128873-A1 | \"6-ARYL-4-PHENYLAMINO-QUINAZOLINE ANALOGS AS PHOSPHOINOSITIDE-3-KINASE INHIBITORS\ | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2015-09-03 | — | — | WO | disclosed |
| WO-2015128873-A1 | \"6-ARYL-4-PHENYLAMINO-QUINAZOLINE ANALOGS AS PHOSPHOINOSITIDE-3-KINASE INHIBITORS\ | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2015-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202374-B2 | 6-aryl-4-phenylamino-quinazoline analogs as phosphoinositide-3-kinase inhibitors | PIK3CA, PI4KA, PDPK1 | PIK3CG 5/4885PIK3CA 1/4885PIK3CD 4/4885 |
| US-20170015662-A1 | 6-ARYL-4-PHENYLAMINO-QUINAZOLINE ANALOGS AS PHOSPHOINOSITIDE-3-KINASE INHIBITORS | PIK3CA, PI4KA, PDPK1 | PIK3CG 5/4885PIK3CA 1/4885PIK3CD 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.